News Quantified

RPRX – royalty pharma plc - class a ordinary shares (US:NASDAQ)

Teva, Medincell granted FDA review for long-acting antipsychotic [Seeking Alpha]

2/16

03:43 am

rprx

Low

Royalty Pharma: 2025 Financial Performance And Strategic Outlook [Seeking Alpha]

Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend [Yahoo! Finance]

Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.

Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View [Seeking Alpha]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}